Genmab A/S
Genmab A/S (GNMSF) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · GNMSF · as of Jun 9, 2026
Key Statistics
Explore Genmab A/S Data
gnmsf stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 11 · Buy rate: 54.5%
Competitors & Peers
gnmsf competitorsGNMSF
ALPMF
ALPMY
BMXXY
GIKLY
IVBXFStock Performance
Full HistoryAbout Genmab A/S
Genmab A/S founded in 1999 and based in Copenhagen, Denmark, is a biopharmaceutical firm focused on developing antibody-based therapeutics to treat cancer and a range of other diseases. The company m…
what is genmab a/s · gnmsf stock overview · genmab a/s company profile · who is genmab a/s ceo · gnmsf OTC · genmab a/s headquarters · genmab a/s business segments
About Stock Overview & Key Data
Genmab A/S (GNMSF) is a Healthcare company in the Biotechnology industry, listed on OTC since Jan 5, 2010. As of the latest trading session, GNMSF stock price is $249.45, with a market capitalization of $15.3B. The stock has returned +14.36% over the past 12 months and -20.56% year-to-date.
According to 11 Wall Street analysts, the consensus rating for Genmab A/S stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Genmab A/S reported revenue of $3.9B and net income of $996.9M. For detailed data — including Genmab A/S revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Genmab A/S (GNMSF) stock price is $249.45. The stock is traded on OTC under the ticker symbol GNMSF. The 52-week range is $198.51 – $352.00.